8-K: Aclaris ATI-052 Phase 1a Results Exceed Expectations

Aclaris Therapeutics announced positive interim Phase 1a results for its bispecific antibody ATI-052, showing a favorable safety profile, best-in-class pharmacokinetic profile, and strong pharmacodynamic effects, supporting potential quarterly dosing and accelerated clinical development.

Summary

• Aclaris Therapeutics reported positive interim results from the first-in-human Phase 1a single (SAD) and multiple ascending dose (MAD) trial of its anti-TSLP/IL-4R bispecific antibody, ATI-052.
• ATI-052 was well tolerated and demonstrated a favorable safety profile across all SAD and MAD cohorts, with doses of up to 720 mg.
• Treatment-emergent adverse events (TEAEs) were predominantly Grade 1, with no Grade 3 TEAEs related to study drug or serious adverse events, and no adverse events leading to study discontinuation.
• The drug exhibited a potential best-in-class pharmacokinetic (PK) profile, including at least a 26-day effective half-life, and dose proportional PK was observed across the pharmacologic dose range.
• Pharmacodynamic (PD) results from the first three SAD cohorts showed robust target engagement and near complete target occupancy at very low doses.
• At 120 mg, ATI-052 demonstrated complete and sustained inhibition of ex vivo IL-4 and TSLP stimulated CCL17/TARC through week one, with near complete inhibition of TSLP stimulated CCL17/TARC observed at least three weeks after administration.
• At 360 mg, ATI-052 demonstrated complete and sustained inhibition of ex vivo IL-4 and TSLP stimulated CCL17/TARC through week three, with near complete inhibition of TSLP stimulated CCL17/TARC observed at least six weeks after administration.
• The combination of PK duration and strong, sustained PD effect supports the potential for up to every three-month dosing.
• The company expects to initiate a Phase 1b Proof-of-Concept (POC) trial in atopic dermatitis (AD) imminently and a Phase 1b POC trial in asthma in the first quarter of 2026.
• Top-line data from both Phase 1b trials are expected in the second half of 2026.
• Planning is underway for a Phase 2b trial of ATI-052 in AD, which the company expects to initiate in the second half of 2026.

Sentiment

Score: 9

Explanation: The filing reports exceptionally positive interim Phase 1a clinical trial results for ATI-052, highlighting a strong safety profile, best-in-class pharmacokinetic and pharmacodynamic characteristics, and the potential for significantly extended dosing intervals. Management explicitly stated results 'exceeded expectations' and announced accelerated development plans, indicating a highly favorable outlook for this key pipeline asset.

Positives

• ATI-052 was well tolerated and demonstrated a favorable safety profile across all SAD and MAD cohorts, with doses up to 720 mg.
• Treatment-emergent adverse events (TEAEs) were predominantly Grade 1, with no Grade 3 TEAEs related to study drug or serious adverse events, and no study discontinuations.
• No conjunctivitis was observed in any cohort.
• ATI-052 exhibited a potential best-in-class pharmacokinetic (PK) profile, including at least a 26-day effective half-life.
• Dose proportional PK was observed across the pharmacologic dose range, with dose proportional increases in Cmax and AUC.
• Pharmacodynamic (PD) results showed robust target engagement and near complete target occupancy at very low doses.
• Complete and sustained inhibition of ex vivo IL-4 and TSLP stimulated CCL17/TARC was observed through week one at 120 mg and through week three at 360 mg.
• Near complete inhibition of TSLP stimulated CCL17/TARC was observed at least three weeks after administration at 120 mg and at least six weeks after administration at 360 mg.
• The combination of PK duration and strong, sustained PD effect supports the potential for up to every three-month dosing.
• Accelerated clinical development plans, with Phase 1b POC trials in AD and asthma initiating imminently/Q1 2026, and a Phase 2b AD trial planned for H2 2026.
• ATI-052 demonstrated greater potency than the combination of Dupilumab and Tezepelumab (IC50 of 0.016 nM vs 0.069 nM, a 4.3-fold difference).
• ATI-052 exhibits the broadest activity among tested biologics for IL-4, IL-13, and TSLP-induced CCL17 release.
• Residence time for ATI-052 is approximately 30-116 times longer than comparator antibodies like Tezepelumab and Solrikitug/MK-8226.

Risks

• Uncertainties inherent in the conduct of clinical trials.
• Potential changes to interim, topline, and preliminary data as more subject data become available.
• Reliance on third parties over which the company may not always have full control.
• Ability to enter into strategic partnerships on commercially reasonable terms.
• Uncertainty regarding the macroeconomic environment.
• Other risks and uncertainties described in the Risk Factors section of the company's Annual Report on Form 10-K for the year ended December 31, 2024.

Future Outlook

Aclaris Therapeutics expects to rapidly advance ATI-052's clinical development, initiating a Phase 1b proof-of-concept trial in atopic dermatitis imminently and another in asthma in the first quarter of 2026. Top-line data from both Phase 1b trials are anticipated in the second half of 2026. The company is also planning to initiate a Phase 2b trial for ATI-052 in atopic dermatitis in the second half of 2026, with the potential for up to every three-month dosing based on current data. Further assessments for additional Phase 2 indications are also planned.

Management Comments

• "Aclaris has experienced significant momentum across our pipeline over the past few months; consistent with that strong momentum, we are pleased to report positive interim results from our Phase 1a SAD/MAD trial of ATI-052 that exceeded our expectations." Dr. Neal Walker, Chief Executive Officer of Aclaris.
• "ATI-052 demonstrated a strong safety and tolerability profile, dose proportional pharmacokinetic profile, and concentration-dependent pharmacodynamics even at the lowest dose – all of which support its best-in-class potential in a variety of inflammatory and immunological diseases due to its ability to uniquely impact multiple pathways of inflammation." Dr. Neal Walker, Chief Executive Officer of Aclaris.
• "These impressive results further validate ATI-052 and reinforce its potential best-in-class potency; given these results, we are rapidly advancing the clinical development of the compound." Dr. Neal Walker, Chief Executive Officer of Aclaris.
• "We expect to initiate Phase 1b proof-of-concept trials in AD and asthma shortly, and planning is already underway for initiation of a Phase 2b trial in AD in the second half of 2026." Dr. Neal Walker, Chief Executive Officer of Aclaris.

Industry Context

ATI-052 is an investigational humanized anti-TSLP and anti-IL-4R bispecific antibody, targeting two key pathways (TSLP and IL-4R/IL-4/IL-13) involved in Th2-mediated inflammation and allergic diseases. This dual blockade approach, combined with its potential best-in-class potency, extended half-life (engineered for tighter FcRn binding), and long residence time on TSLP, positions it as a potentially superior treatment option compared to existing or developing monoclonal antibodies that target single pathways (e.g., Tezepelumab for TSLP, Dupilumab for IL-4R). The potential for up to every three-month dosing could offer a significant convenience advantage for patients in chronic conditions like atopic dermatitis and asthma, potentially disrupting the market for current biologics requiring more frequent administration.

Comparison to Industry Standards

• ATI-052 demonstrated greater potency (IC50 of 0.016 nM) than the combination of Dupilumab and Tezepelumab (IC50 of 0.069 nM) in cellular bioactivity on CCL17 release, representing a 4.3-fold difference.
• ATI-052 exhibits the broadest activity among tested biologics (Dupilumab, Lebrikizumab, Tezepelumab, Tralokinumab) across IL-4, IL-13, and TSLP-induced CCL17 release assays.
• The residence time for ATI-052 on TSLP is approximately 30-116 times longer than comparator antibodies such as Tezepelumab and Solrikitug/MK-8226, suggesting a sustained therapeutic effect.
• The effective half-life of at least 26 days and strong pharmacodynamic effect support potential for up to every three-month dosing, which could be a significant advantage over current monthly or bi-weekly injectable biologics for conditions like atopic dermatitis and asthma.

Stakeholder Impact

• Shareholders: Highly positive news, likely to increase investor confidence and potentially share price due to strong clinical data and accelerated development of a key pipeline asset with "best-in-class" potential.
• Patients: Potential for a new, highly effective treatment option for immuno-inflammatory diseases like atopic dermatitis and asthma, with the added benefit of less frequent dosing (up to every three months).
• Employees: Positive momentum for the company, potentially leading to increased R&D investment and job security.
• Competitors: May face increased competitive pressure from a potentially superior product with a more convenient dosing schedule.

Next Steps

• Initiate Phase 1b Proof-of-Concept (POC) trial in atopic dermatitis (AD) imminently.
• Initiate Phase 1b POC trial in asthma in the first quarter of 2026.
• Report top-line data from both Phase 1b trials in the second half of 2026.
• Initiate Phase 2b trial of ATI-052 in AD in the second half of 2026.
• Complete assessments of additional Phase 2 indications (e.g., COPD, EOE, Prurigo Nodularis, Chronic Spontaneous Urticaria).
• Present SAD 720 mg cohort and MAD 240/480 mg cohort data at a future medical meeting once complete.

Key Dates

Recommendation

The interim Phase 1a results for ATI-052 are exceptionally strong, demonstrating a favorable safety profile, potential best-in-class pharmacokinetics (26-day half-life, supporting quarterly dosing), and robust pharmacodynamics with superior potency compared to existing combination therapies like Dupilumab and Tezepelumab. The accelerated clinical development timeline, with Phase 1b trials initiating imminently and Phase 2b planning underway, indicates high confidence from management and significantly de-risks this key pipeline asset. The potential for a quarterly dosing regimen offers a substantial competitive advantage in patient convenience for chronic conditions. These factors collectively suggest a strong positive outlook for the company's valuation and future growth.

Keywords

Aclaris Therapeutics, ATI-052, bispecific antibody, TSLP, IL-4R, Phase 1a, clinical trial, atopic dermatitis, asthma, immuno-inflammatory diseases, pharmacokinetics, pharmacodynamics, safety, tolerability, drug development, biopharmaceutical